Apixaban Intermediate CAS 503614-91-3 Purity ≥99.0% (HPLC) Factory High Quality
Ruifu Chemical is the leading manufacturer of Apixaban Intermediate (CAS: 503614-91-3) with high quality.
Ruifu Chemical has been supplying pharmaceutical intermediates and APIs (Active Pharmaceutical Ingredients) more than 15 years.
Ruifu Chemical can provide worldwide delivery, competitive price, excellent service.
Purchase Apixaban Intermediates, please contact us by e-mail: alvin@ruifuchem.com
| Chemical Name | 1-(4-Methoxyphenyl)-7-oxo-6-[4-(2-oxopiperidin-1-yl)phenyl]-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxylic acid ethyl ester |
| Synonyms | Ethyl 1-(4-methoxyphenyl)-7-oxo-6-(4-(2-oxopiperidin-1-yl)phenyl)-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxylate; Apixaban Intermediate; Apixaban V; Apixaban Impurity 9; Apixaban Ethyl Ester Impurity; Apixaban Ethyl Ester |
| Stock Status | In Stock, Commercial Production |
| CAS Number | 503614-91-3 |
| Molecular Formula | C27H28N4O5 |
| Molecular Weight | 488.54 g/mol |
| Melting Point | 175.0~180.0℃ |
| Density | 1.34 |
| Storage | 2-8℃ Refrigerator |
| Shipping Conditions | Ambient |
| COA & MSDS | Available |
| Origin of Product | Shanghai, China |
| Product Categories | Apixaban Intermediates |
| Reference Standard | In-house Standard |
| Brand | Ruifu Chemical |
| Items | Specifications | Results |
| Appearance | Off-White to Pale Yellow Powder | Off-White Powder |
| Identification | The retention time of the major peak of the sample solution corresponds to that of the standard solution | Complies |
| Water by Karl Fischer | ≤0.50% | 0.11% |
| Related Substances | ||
| Individual Impurities | ≤0.30% | 0.13% |
| Total Impurities | ≤1.00% | 0.27% |
| Purity / Analysis Method | ≥99.0% (HPLC) | 99.73% |
| 1H NMR Spectrum | Conforms to Structure | Conforms |
| Conclusion | The product has been tested and complies with the given specifications | |
Package: Fluorinated bottle, aluminium foil bag, 25kg/cardboard drum, or according to customer's requirement.
Storage Condition: Keep the container tightly closed. Store in a cool, dry (2-8℃) and well-ventilated warehouse away from incompatible substances. Keep away from sunshine; avoid fire and heat sources; avoid moisture.
Shipping: Deliver to worldwide by air, by FedEx / DHL Express. Provide fast and reliable delivery.
How to Purchase? Please contact Dr. Alvin Huang: sales@ruifuchem.com or alvin@ruifuchem.com
15 Years Experience? We have more than 15 years of experience in the manufacture and export of a wide range of high quality pharmaceutical intermediates or fine chemicals.
Main Markets? Sell to domestic market, North America, Europe, India, Korea, Japanese, Australia, etc.
Advantages? Superior quality, affordable price, professional services and technical support, fast delivery.
Quality Assurance? Strict quality control system. Professional equipment for analysis include NMR, LC-MS, GC, HPLC, ICP-MS, UV, IR, OR, K.F, ROI, LOD, MP, Clarity, Solubility, Microbial limit test, etc.
Samples? Most products provide free samples for quality evaluation, shipping cost should be paid by customers.
Factory Audit? Factory audit welcome. Please make an appointment in advance.
MOQ? No MOQ. Small order is acceptable.
Delivery Time? If within stock, three days delivery guaranteed.
Transportation? By Express (FedEx, DHL), by Air, by Sea.
Documents? After sales service: COA, MOA, ROS, MSDS, etc. can be provided.
Custom Synthesis? Can provide custom synthesis services to best fit your research needs.
Payment Terms? Proforma invoice will be sent first after confirmation of order, enclosed our bank information. Payment by T/T (Telex Transfer), PayPal, Western Union, etc.
1-(4-Methoxyphenyl)-7-oxo-6-[4-(2-oxopiperidin-1-yl)phenyl]-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxylic acid ethyl ester (CAS: 503614-91-3) is an intermediate for the preparation of apixaban. apixaban is an antithrombotic drug. It is a direct inhibitor of factor Xa jointly developed by Bristol-Myers Squibb and Pfizer. It was approved for listing in the European Union in March 2011, and F DA approved the drug for listing in the United States in December 2012.
